Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoHIP
NCT03747120Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2019
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in breast cancer (3 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Pathological Complete Response at 16 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03747120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747120.